首页> Journal of the American College of Cardiology> The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

导出 LinkOut

翻译打印收藏纠错

第一作者： Paul A,Reilly

第一单位： Departments of Clinical Development and Clinical Biostatistics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut. Electronic address: paul.reilly@boehringer-ingelheim.com.

作者： Paul A,Reilly ^[1] ; Thorsten,Lehr ^[2] ; Sebastian,Haertter ^[3] ; Stuart J,Connolly ^[4] ; Salim,Yusuf ^[4] ; John W,Eikelboom ^[4] ; Michael D,Ezekowitz ^[5] ; Gerhard,Nehmiz ^[3] ; Susan,Wang ^[6] ; Lars,Wallentin ^[7] ; RE-LY Investigators

作者单位： Departments of Clinical Development and Clinical Biostatistics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut. Electronic address: paul.reilly@boehringer-ingelheim.com. ^[1] Departments of Translational Medicine and Biometry, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Saarland University, Saarbrücken, Germany. ^[2] Departments of Translational Medicine and Biometry, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. ^[3] Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. ^[4] Jefferson Medical College, Wynnewood, Pennsylvania. ^[5] Departments of Clinical Development and Clinical Biostatistics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut. ^[6] Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ^[7]